.RESEARCH FEATURE.06 August 2024.
A huge randomized controlled trial with cisgender ladies highlights the difficulties of adherence to an everyday oral preexposure prevention regiment as well as illustrates that twice-yearly treatment of lenacapavir can easily keep effective HIV protection levels over 6 months.